Skip to main content
Premium Trial:

Request an Annual Quote

Scott Kahn, Paul Grint, Scott Greer, David Skiados


Scott Kahn has been named vice president and chief information officer of Illumina, the company announced last week.

Kahn comes to Illumina from Accelrys, where he served as chief scientific officer. He also worked in product development and marketing at BioCAD and Molecular Simulations.

Kahn holds a PhD in theoretical organic chemistry from the University of California, Irvine. He is a former assistant professor of chemistry at the University of Illinois, Urbana-Champaign.

San Diego-based Illumina also announced last week that Paul Grint has joined its board of directors.

Grint is currently senior vice president and chief medical officer of Zephyr Sciences, a biopharmaceutical company. Prior to joining Zephyr, Grint was vice president and head of clinical R&D at Pfizer in La Jolla, Calif. He previously held administrative positions at IDEC Pharmaceuticals, Schering-Plough, and Wellcome Research Laboratories.

Grint received his MD from the University of London, St. Bartholomew's Hospital Medical College in the UK.

He replaces Scott Greer, an Illumina board member since May 2001 and the chairman of Abgenics. Greer resigned from the board last week.

Hitachi last week appointed David Skiados as its USA director of sales for its High Technologies America subsidiary, the company said.

Prior to joining Hitachi HTA, Skiados held sales and business development positions at MWG Biotech, Ionics, and PerkinElmer/ABI. Skiados also served as a senior staff scientist at the National Institute of Allergy and Infectious Diseases.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.